IT1397247B1 - Nuovi agenti regolatori dell'attivita' citochinica - Google Patents

Nuovi agenti regolatori dell'attivita' citochinica

Info

Publication number
IT1397247B1
IT1397247B1 ITPD2009A000135A ITPD20090135A IT1397247B1 IT 1397247 B1 IT1397247 B1 IT 1397247B1 IT PD2009A000135 A ITPD2009A000135 A IT PD2009A000135A IT PD20090135 A ITPD20090135 A IT PD20090135A IT 1397247 B1 IT1397247 B1 IT 1397247B1
Authority
IT
Italy
Prior art keywords
cytokinic
activity
new regulatory
regulatory agents
agents
Prior art date
Application number
ITPD2009A000135A
Other languages
English (en)
Inventor
Devis Galesso
Anna Maria Zanellato
Original Assignee
Fidia Farmaceutici
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ITPD2009A000135A priority Critical patent/IT1397247B1/it
Application filed by Fidia Farmaceutici filed Critical Fidia Farmaceutici
Priority to CN201810521049.XA priority patent/CN108379288B/zh
Priority to ES16178622T priority patent/ES2722436T3/es
Priority to PT107211252T priority patent/PT2429533T/pt
Priority to SI201031341A priority patent/SI2429533T1/sl
Priority to LTEP10721125.2T priority patent/LT2429533T/lt
Priority to EP10721125.2A priority patent/EP2429533B1/en
Priority to PL10721125T priority patent/PL2429533T3/pl
Priority to PCT/EP2010/003044 priority patent/WO2010130466A1/en
Priority to ES10721125.2T priority patent/ES2602498T3/es
Priority to EP16178622.3A priority patent/EP3103459B1/en
Priority to US13/320,015 priority patent/US9808482B2/en
Priority to RU2011146049/15A priority patent/RU2552337C2/ru
Priority to CA2967567A priority patent/CA2967567C/en
Priority to CN201080020643.2A priority patent/CN102421443B/zh
Priority to HUE10721125A priority patent/HUE031174T2/en
Priority to CA2761627A priority patent/CA2761627C/en
Publication of ITPD20090135A1 publication Critical patent/ITPD20090135A1/it
Publication of IT1397247B1 publication Critical patent/IT1397247B1/it
Application granted granted Critical
Priority to HRP20161575TT priority patent/HRP20161575T8/hr
Priority to SM201600456T priority patent/SMT201600456B/it
Priority to US15/710,275 priority patent/US10548918B2/en
Priority to HK19101455.5A priority patent/HK1258973A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
ITPD2009A000135A 2009-05-14 2009-05-14 Nuovi agenti regolatori dell'attivita' citochinica IT1397247B1 (it)

Priority Applications (21)

Application Number Priority Date Filing Date Title
ITPD2009A000135A IT1397247B1 (it) 2009-05-14 2009-05-14 Nuovi agenti regolatori dell'attivita' citochinica
RU2011146049/15A RU2552337C2 (ru) 2009-05-14 2010-05-11 Сульфатированные гиалуроновые кислоты в качестве регуляторов цитокиновой активности
US13/320,015 US9808482B2 (en) 2009-05-14 2010-05-11 Sulphated hyaluronic acids as regulator agents of the cytokine activity
SI201031341A SI2429533T1 (sl) 2009-05-14 2010-05-11 Sulfatirane hialuronske kisline kot sredstva za regulacijo citokinske aktivnosti
LTEP10721125.2T LT2429533T (lt) 2009-05-14 2010-05-11 Sulfatuotos hialorono rūgštys, kaip citokinų aktyvumą reguliuojantys agentai
EP10721125.2A EP2429533B1 (en) 2009-05-14 2010-05-11 Sulphated hyaluronic acids as regulator agents of the cytokine activity
PL10721125T PL2429533T3 (pl) 2009-05-14 2010-05-11 Siarczanowane kwasy hialuronowe jako czynniki regulujące aktywność cytokin
PCT/EP2010/003044 WO2010130466A1 (en) 2009-05-14 2010-05-11 Sulphated hyaluronic acids as regulator agents of the cytokine activity
ES10721125.2T ES2602498T3 (es) 2009-05-14 2010-05-11 Ácidos hialurónicos sulfatados como agentes reguladores de la actividad de citoquinas
CA2967567A CA2967567C (en) 2009-05-14 2010-05-11 Sulphated hyaluronic acids as regulator agents of the cytokine activity
CN201810521049.XA CN108379288B (zh) 2009-05-14 2010-05-11 作为细胞因子活性调节剂的硫酸化的透明质酸
PT107211252T PT2429533T (pt) 2009-05-14 2010-05-11 Ácidos hialurónicos sulfatados como agentes reguladores da atividade citoquínica
EP16178622.3A EP3103459B1 (en) 2009-05-14 2010-05-11 Sulphated hyaluronic acids as antiviral agents
CN201080020643.2A CN102421443B (zh) 2009-05-14 2010-05-11 作为细胞因子活性调节剂的硫酸化的透明质酸
HUE10721125A HUE031174T2 (en) 2009-05-14 2010-05-11 Sulfated hyaluronic acids as cytokine activity regulators
CA2761627A CA2761627C (en) 2009-05-14 2010-05-11 Sulphated hyaluronic acids as regulator agents of the cytokine activity
ES16178622T ES2722436T3 (es) 2009-05-14 2010-05-11 Acidos hialurónicos sulfatados como agentes antivirales
HRP20161575TT HRP20161575T8 (hr) 2009-05-14 2016-11-25 Sulfatirane hijaluronske kiseline kao sredstva za reguliranje aktivnosti citokina
SM201600456T SMT201600456B (it) 2009-05-14 2016-12-14 Acidi ialuronici solfatati come agenti regolatori dell'attività citochinica
US15/710,275 US10548918B2 (en) 2009-05-14 2017-09-20 Sulphated hyaluronic acids as regulator agents of the cytokine activity
HK19101455.5A HK1258973A1 (zh) 2009-05-14 2019-01-28 作為細胞因子活性調節劑的硫酸化的透明質酸

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITPD2009A000135A IT1397247B1 (it) 2009-05-14 2009-05-14 Nuovi agenti regolatori dell'attivita' citochinica

Publications (2)

Publication Number Publication Date
ITPD20090135A1 ITPD20090135A1 (it) 2010-11-15
IT1397247B1 true IT1397247B1 (it) 2013-01-04

Family

ID=41268269

Family Applications (1)

Application Number Title Priority Date Filing Date
ITPD2009A000135A IT1397247B1 (it) 2009-05-14 2009-05-14 Nuovi agenti regolatori dell'attivita' citochinica

Country Status (16)

Country Link
US (2) US9808482B2 (it)
EP (2) EP2429533B1 (it)
CN (2) CN108379288B (it)
CA (2) CA2761627C (it)
ES (2) ES2602498T3 (it)
HK (1) HK1258973A1 (it)
HR (1) HRP20161575T8 (it)
HU (1) HUE031174T2 (it)
IT (1) IT1397247B1 (it)
LT (1) LT2429533T (it)
PL (1) PL2429533T3 (it)
PT (1) PT2429533T (it)
RU (1) RU2552337C2 (it)
SI (1) SI2429533T1 (it)
SM (1) SMT201600456B (it)
WO (1) WO2010130466A1 (it)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009231634B2 (en) 2008-04-04 2014-05-15 University Of Utah Research Foundation Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
US8343942B2 (en) * 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
IT1397246B1 (it) * 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica
US20130209531A1 (en) 2010-06-08 2013-08-15 University Of Utah Research Foundation Applications of partially and fully sulfated hyaluronan
US9522162B2 (en) 2011-03-23 2016-12-20 University Of Utah Research Foundation Methods for treating or preventing urological inflammation
GB201219696D0 (en) 2012-11-01 2012-12-12 Univ Liverpool Agents for the prevention and/or treatment of central nervous system damamge
US11337994B2 (en) 2016-09-15 2022-05-24 University Of Utah Research Foundation In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
CN109529021B (zh) * 2019-01-25 2022-11-15 山东省分析测试中心 一种白细胞介素2抑制破骨细胞生成和功能的新用途
IT201900003887A1 (it) 2019-03-18 2020-09-18 Fidia Farm Spa Sistemi di stabilizzazione e di rilascio controllato di farmaci instabili alla sterilizzazione
WO2021133000A1 (ko) * 2019-12-23 2021-07-01 주식회사 엘지화학 항염 또는 항혈관신생용 약제학적 조성물
WO2021179047A1 (en) 2020-03-12 2021-09-16 Cullis Hill Sydney David Treatment for coronavirus infection and associated cytokine toxicity
IT202000032243A1 (it) * 2020-12-23 2022-06-23 Fidia Farm Spa Nuovi agenti antivirali

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
IT1217458B (it) * 1988-05-02 1990-03-22 Crinos Ind Farmacoriologica S Sulfoamino derivati di condroitin solfati,del dermatan solfato e dell' acido ialuronico e loro proprieta' farmacologiche
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
DE4021066A1 (de) * 1990-07-03 1992-01-09 Hoechst Ag Langzeitprophylaxe gegen erkrankungen, die durch viren oder durch unkonventionelle viren verursacht werden
ITPD940054A1 (it) * 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
EP0754460B1 (en) * 1995-02-07 2002-06-05 Shiseido Company Limited Antiinflammatory agents
JPH10195107A (ja) * 1997-01-10 1998-07-28 Shiseido Co Ltd オリゴ硫酸化ヒアルロン酸
DK0971961T3 (da) 1997-04-04 2003-03-24 Fidia Advanced Biopolymers Srl N-sulfaterede hyaluronsyreforbindelser, derivater deraf og en fremgangsmåde til deres fremstilling
US5981509A (en) * 1997-05-20 1999-11-09 Shiseido Company, Ltd. Preparation for prophylaxis or treatment of renal diseases containing sulfated polysaccharide
JPH11147901A (ja) * 1997-11-19 1999-06-02 Maruho Co Ltd カリクレイン−キニン系阻害剤
JPH11269077A (ja) * 1998-03-19 1999-10-05 Maruho Co Ltd ホスホリパーゼａ２阻害用医薬組成物
DE19813234A1 (de) * 1998-03-26 1999-09-30 Knoell Hans Forschung Ev Verfahren zur Herstellung hochsulfatierter Hyaluronsäuren
JP2000178196A (ja) 1998-12-11 2000-06-27 Seikagaku Kogyo Co Ltd 新規ヒアルロニダーゼ阻害剤及び外用剤
JP2001163789A (ja) * 1999-12-13 2001-06-19 Maruho Co Ltd マトリックスメタロプロテアーゼ阻害用医薬組成物
GB0003048D0 (en) * 2000-02-11 2000-03-29 Dealler Stephen F The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
US7431920B2 (en) * 2000-07-19 2008-10-07 Pepgen Corporation Method of treating IL-10 deficiency
DE10053053A1 (de) * 2000-10-19 2002-05-16 Knoell Hans Forschung Ev Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden
US20030162732A1 (en) * 2001-07-05 2003-08-28 Astion Development A/S Combination of aminosugars and cysteine or cysteine derivatives
ITPD20020271A1 (it) * 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
DE10349722A1 (de) * 2003-10-23 2005-06-16 Beschorner, Katharina, Dr. Zusammensetzung zur Arthrose-/Arthritisbehandlung, insbesondere von Gelenken
DE10352137A1 (de) * 2003-11-04 2005-06-16 Beschorner, Katharina, Dr. Verwendung sulfatierter Hyaluronsäure
ITPD20040245A1 (it) * 2004-10-08 2005-01-08 Fidia Advanced Biopolymers Srl Biomateriali costituiti da acido ialuronico solfatato e gellano utilizzabili nella prevenzione delle adesioni spinali
DE102005004643B4 (de) * 2005-01-28 2010-04-08 Innovent E.V. Technologieentwicklung Antivirale Kombinationen sowie ihre Verwendung
ITPD20050168A1 (it) * 2005-06-01 2006-12-02 Fidia Advanced Biopolymers Srl Formulazioni di acido lipoico ed acido ialuronico e o suoi derivati e loro impiego in campo farmaceutico e cosmetico
US7517856B2 (en) * 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
JP4220513B2 (ja) * 2005-12-01 2009-02-04 株式会社資生堂 カチオン化ヒアルロン酸
ITPD20060219A1 (it) * 2006-05-31 2007-12-01 Fidia Farmaceutici Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi
EP2025687A1 (en) * 2007-07-23 2009-02-18 Istituto Scientifico di Chimica E Biochimica "G Ronzoni Process for the preparation of heparanase-inhibiting sulfated hyaluronates and products obtained thereby
EP2090308A1 (en) * 2008-02-15 2009-08-19 Bone Therapeutics Pharmaceutical composition for the treatment or prevention of osteoarticular diseases
IT1397246B1 (it) * 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica

Also Published As

Publication number Publication date
CA2967567A1 (en) 2010-11-18
US20180008628A1 (en) 2018-01-11
SI2429533T1 (sl) 2017-01-31
US20120101059A1 (en) 2012-04-26
CN102421443B (zh) 2018-06-26
HRP20161575T8 (hr) 2019-01-25
ES2722436T3 (es) 2019-08-12
EP3103459A3 (en) 2017-01-18
LT2429533T (lt) 2016-12-12
EP3103459B1 (en) 2019-02-27
PT2429533T (pt) 2016-11-14
EP2429533B1 (en) 2016-09-07
EP3103459A2 (en) 2016-12-14
HRP20161575T1 (hr) 2016-12-30
US10548918B2 (en) 2020-02-04
CA2761627C (en) 2017-07-04
RU2011146049A (ru) 2013-06-20
RU2552337C2 (ru) 2015-06-10
ES2602498T3 (es) 2017-02-21
US9808482B2 (en) 2017-11-07
EP2429533A1 (en) 2012-03-21
CN108379288A (zh) 2018-08-10
HK1258973A1 (zh) 2019-11-22
HUE031174T2 (en) 2017-06-28
ITPD20090135A1 (it) 2010-11-15
SMT201600456B (it) 2017-01-10
WO2010130466A1 (en) 2010-11-18
CN102421443A (zh) 2012-04-18
CA2967567C (en) 2018-09-11
CN108379288B (zh) 2020-10-16
CA2761627A1 (en) 2010-11-18
PL2429533T3 (pl) 2017-02-28

Similar Documents

Publication Publication Date Title
IT1397247B1 (it) Nuovi agenti regolatori dell'attivita' citochinica
CY2019031I2 (el) Αναπνευστικη απελευθερωση ενεργων παραγοντων
SMT201500196B (it) Derivati dell'acido idrossammico
SMT201500054B (it) 2-Anilinobenzimidazolo-6-carbossammidi come agentianti-infiammattori
SMT201500053B (it) 2-Amminobenzimidazol-5-carbossammidi come agenti nati-infiammatori
BRPI1012129A2 (pt) enantiômeros de compostos spiro-oxindol e sua utilização como agentes terapêuticos.
SMT201600332B (it) Composizioni e metodi per l’aumento dell’attivitàtelomerasica
SMT201700014B (it) Agenti terapeutici per la riduzione dei livelli dell'ormone paratiroideo
BR112012021374A2 (pt) " plataforma de pernas atirantadas "
FR2957244B1 (fr) Implant d'arthrodese
BRPI0916931A2 (pt) agentes terapêuticos
BR112013000705A2 (pt) "composição de limpeza para cuidado pessoal"
BR112012025270A2 (pt) "composição de cuidados pessoais"
SMT201600041B (it) Agenti terapeutici 713
DK2648741T3 (da) Hjertebeskyttende midler fra kiwifrugter
BRPI0917210A2 (pt) exoterma controlada de formulações de cianocrilato
IT1395539B1 (it) Piede d'appoggio
IL225717A0 (en) Arylsulfonamide salts as ccr3 antagonists
FR2976520B1 (fr) Pneumatique comprenant des temoins d'usure sonores monobarettes
BRPI1014457A2 (pt) "n-(4-perfluoro-alquil-fenil)-4-triazolil-benzamidas como inseticidas"
IT1397522B1 (it) Uso di una combinazione per il trattamento dell'osteoartrosi
IT1397212B1 (it) Derivati di amminoalcoli e loro attivita' terapeutica
FR2970577B1 (fr) Plateforme d'execution modulaire amelioree.
BRPI0911543A2 (pt) arilciclopentenos substituídos como agentes terapêuticos
IT1404729B1 (it) Inibitori altamente selettivi dell'attivita' di adams